Shanghai Pharmaceuticals Holding Co., Ltd.(hereinafter as Shanghai Pharma, SSE stock code 601607 and HKEx stock code 02607) is a large pharmaceutical group to have a dual-listing in the stock exchanges of Shanghai and Hong Kong.The Company’s principal business covers pharmaceutical R&D, manufacturing, distribution and retailing. In 2016, the Company had reportedly the business revenues of RMB 120.8 billion, ranking among the country’s comprehensive strength in the forefront of the industry. The Company is the one of the few listed pharmaceutical companies which holds a leading position in both pharmaceutical manufacturing and distribution in China.It is selected into the sample stocks of both the SSE 180 Index and CSI 300 Index, with its H shares selected into the Hang Seng Index Compositional Stocks and MSCI.
Adhering to innovation, Shanghai Pharma’s Research and development is dedicated to providing safe and effective drugs against the grave and chronic diseases. The total amount of R&D investment of the Company was accounting for 5.40% of manufacturing sales.The Company has built up the R&D systems with the Central Research Institute acting as the technical core. The Company owns 1 State-level corporate technology center and 10 provincial/city-level corporate technology centers. Shanghai Pharma has accumulated 319 invention patents in total.Two cooperative projects won "the First-class National Scientific and Technological Progress Award of 2014 and 2015”. The Company adopts an open mode of R&D, under which the Company has built up the strategic alliance of innovative drug R&D in collaboration with Shanghai Institute of Materia Medica,China Pharmaceutical University ,Shenyang Pharmaceutical University,Mitsubishi Tanabe Pharma Corporation, the Second Military Medical University,Shanghai Fudan Zhangjiang Biopharm etc. Many innovative products are in the registration or clinical trial stages.
Shanghai Pharma’s manufacturing business provides products ranging from chemical and bio-pharms, modern Chinese medicine, healthcare products and medical devices etc., Shanghai Pharmaceuticals is focused on five therapeutic areas of digestive and metabolic systems, cerebral and cardio vascular diseases, antiinfection,neuro-psycho diseases and oncology. It has manufacturing bases in 8 provinces, including a specialist API base, a modern TCM (Traditional Chinese Medicine) base, a fine chemical reagent factory and a health care products production base.The products are made in over 20 dosage forms, 26 products have sales revenue over RMB 100 million. The Company runs a number of brands, such as SINE, Leishi, Dragon & Tiger, Cangsong, Guofeng and Shengxiang, all of which are the renowned Chinese trademarks, and is authorized to use the well-known trademarks of Qingchunbao and Huqingyutang. Production lines are all passed the new GMP certification,The company has adopted the lean management system, optimized production and conducted pilot programs on integrating informatization and industrialization..The company has a number of APIs and preparations passed the quality authentication imposed by WHO, FDA, EU and other developed countries.
Shanghai Pharma’s distribution networks focus on the Eastern China, Northern China and Southern part of China, which are the most developed areas in China, and radiates out to other areas in the country. The Company’s distribution business ranks the top 3 position in size. The Company established a close cooperation relationship with domestic and foreign major drug manufacturers through supply chain solutions such as modern logistics delivery,information support and terminal retail distribution.It covers more than 25,000 healthcare institutions. The Company has a nationwide commercial network and an efficient, agile, smart and modern supply chain service channel.The Company holds a leading position in new business development in China in respect of vaccines, high-end consumables, DTP and SPD.
Shanghai Pharma’s retail is ranked among the top players in the nationwide drug-retailing industry in terms of sales revenues and the Huashi Pharmacy is one of the largest chain drugstores in East China area.,with a sales network comprising of about 1800 drugstores covering 16 provinces, autonomous regions and municipalities. The retailing business of Shanghai Pharma includes diversified business models, comprising the chain drugstores, joint-venture drugstores and DTP drugstores etc. They carry out the in-depth integration of internal retail resources using “Huashi” as the platform and modern information technology as the carrier to expand Tmall store, remote video pharmic counseling, medicine retail network, self-help medicine-purchasing machine and other new health service models. The company is exploring the new pharmaceutical business mode, SPH Health Cloud cooperated with Jingdong, Wanda, DXY etc.,providing service platform to focus on consumer experience and more professional services, more convenient ways for drug purchase and more comprehensive health management.
Adhering to the corporate’s core conceptions that are described as “innovation, integrity, cooperation, inclusiveness and responsibility”, Shanghai Pharma is always dedicated to the enhancement of people’s enjoyment of a healthier living condition, while endeavoring to be recognized as an esteemed manufacturer of the leading-brand pharmaceutical products and service provider in the healthcare industry with a sound reputation.See more